Maintenance Treatment and Survival in Patients With Myeloma

Abstract

Background: The evolution of treatment strategies for multiple myeloma (MM) has significantly transformed patient outcomes over the past two decades. This literature review explores the intricate relationship between maintenance treatment and survival in patients with myeloma, drawing upon several pivotal studies that chart this trajectory.  Literature Review: The main body of the review elaborates on several pivotal studies that contribute to the understanding of maintenance therapies. The examination of post-transplant maintenance therapy reveals that achieving a complete response and MRD negativity post-ASCT correlates with improved progression-free survival (PFS) and overall survival (OS) (Sengsayadeth et al., 2017). The exploration of relapsed and refractory MM highlights the ongoing need for novel agents and personalized treatment approaches to sustain treatment efficacy (S. Nijhof et al., 2018). A meta-analysis of randomized controlled trials indicates that while conventional maintenance therapies have limited efficacy, newer regimens incorporating innovative agents significantly improve PFS (Li et al., 2018). The findings from the Myeloma XI study further substantiate the superiority of lenalidomide maintenance therapy in extending PFS, emphasizing the importance of deep responses and sustained MRD negativity (Goldschmidt et al., 2018). Additionally, the exploration of future directions in maintenance therapy raises critical questions regarding the optimal duration and composition of treatments, advocating for a personalized approach based on patient-specific factors (A. Holstein et al., 2011).  Conclusion: The review concludes by underscoring the necessity of integrating lifestyle interventions to enhance the quality of life for MM patients, recognizing that the long-term effects of treatment can significantly impact patient well-being (N. Shapiro et al., 2011). Collectively, the articles illustrate a dynamic and evolving landscape in the management of multiple myeloma, emphasizing the critical role of maintenance therapy in improving survival outcomes and the necessity for ongoing research to optimize treatment strategies.